In the present study, the response of 30 consecutive chronic lymphocytic leukemia (CLL) patients to bendamustine and rituximab treatment was evaluated according to TSPO expression levels. The gene discussed is TSPO; the disease is B-cell chronic lymphocytic leukemia.